Premium
Variant Creutzfeldt‐Jakob disease and exposure to fractionated plasma products
Author(s) -
Ward H. J. T.,
MacKenzie J. M.,
Llewelyn C. A.,
Knight R. S. G.,
Hewitt P. E.,
Connor N.,
Molesworth A.,
Will R. G.
Publication year - 2009
Publication title -
vox sanguinis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.68
H-Index - 83
eISSN - 1423-0410
pISSN - 0042-9007
DOI - 10.1111/j.1423-0410.2009.01205.x
Subject(s) - medicine , disease , creutzfeldt jakob syndrome , transmission (telecommunications) , haemophilia , blood transfusion , epidemiology , haemophilia a , receipt , pediatrics , surgery , prion protein , world wide web , computer science , electrical engineering , engineering
Background The risk to public health of onward transmission of variant Creutzfeldt–Jakob disease (vCJD) via blood transfusion and plasma product administration is of on‐going concern, particularly with the recent reported detection of abnormal prion protein in a person with haemophilia. Objectives To describe the history of fractionated plasma product exposure in clinical cases of vCJD in the UK. Methods Through examination of records held at the National CJD Surveillance Unit (from relatives, general practices and hospitals). Results Nine out of 168 UK vCJD cases had a history of receipt of fractionated plasma products on 12 different occasions (1 pre‐vCJD risk in 1970, the remaining between 1989–1998). According to the UK CJD Incident Panel risk assessment criteria, 11 were low‐risk products and one was low or medium risk. Conclusion It is unlikely that any of the UK vCJD clinical cases to date were infected through exposure to fractionated plasma products. However, the possibility that such transmission may result in vCJD cases in the future cannot be excluded.